Abstract:Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.See Duran-Aniotz et al. (doi 10.1093/brain/awv401) for a scientific commentary on this article.Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.The aberrant accumulation of toxic protein aggregates is a key feature of many neurodegenerative diseases, including Huntington's disease, amyotrophic lateral sclerosis and Alzheimer's disease. As such, improving normal proteostatic mechanisms is an active target for biomedical research. Although they share common pathological features, protein aggregates form in different subcellular locations. N epsilon-lysine acetylation in the lumen of the endoplasmic reticulum has recently emerged as a new mechanism to regulate the induction of autophagy. The endoplasmic reticulum acetylation machinery includes AT-1/SLC33A1, a membrane transporter that translocates acetyl-CoA from the cytosol into the endoplasmic reticulum lumen, and ATase1 and ATase2, two acetyltransferases that acetylate endoplasmic reticulum cargo proteins. Here, we used a mutant form of alpha-synuclein to show that inhibition of the endoplasmic reticulum acetylation machinery specifically improves autophagy-mediated disposal of toxic protein aggregates that form within the secretory pathway, but not those that form in the cytosol. Consequently, haploinsufficiency of AT-1/SLC33A1 in the mouse rescued Alzheimer's disease, but not Huntington's disease or amyotrophic lateral sclerosis. In fact, intracellular toxic protein aggregates in Alzheimer's disease form within the secretory pathway while in Huntington's disease and amyotrophic lateral sclerosis they form in different cellular compartments. Furthermore, biochemical inhibition of ATase1 and ATase2 was also able to rescue the Alzheimer's disease phenotype in a mouse model of the disease. Specifically, we observed reduced levels of soluble amyloid-beta aggregates, reduced amyloid-beta pathology, reduced phosphorylation of tau, improved synaptic plasticity, and increased lifespan of the animals. In conclusion, our results indicate that N epsilon-lysine acetylation in the endoplasmic reticulum lumen regulates normal proteostasis of the secretory pathway; they also support therapies targeting endoplasmic reticulum acetyltransferases, ATase1 and ATase2, for a subset of chronic degenerative diseases.

3-Hydroxyanthranilic Acid Delays Paralysis in Caenorhabditis elegans Models of Amyloid-Beta and Polyglutamine Proteotoxicity

On the benefits of the tryptophan metabolite 3-hydroxyanthranilic acid in Caenorhabditis elegans and mouse aging

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

3-hydroxyanthranilic acid – a new metabolite for healthy lifespan extension

Ursolic Acid Ameliorates Amyloid Β-Induced Pathological Symptoms in Caenorhabditis Elegans by Activating the Proteasome.

Carnosic Acid Ameliorated Aβ-mediated (Amyloid-Β Peptide) Toxicity, Cholinergic Dysfunction and Mitochondrial Defect in Caenorhabditis Elegans of Alzheimer's Model.

The Emerging Role of 3-Hydroxyanthranilic Acid on Aging Immune Function

N-3 Polyunsaturated Fatty Acids Attenuate Amyloid-Beta-induced Toxicity in AD Transgenic Caenorhabditis Elegans Via Promotion of Proteasomal Activity and Activation of PPAR-gamma.

Lacticaseibacillus rhamnosus HA-114 and Bacillus subtilis R0179 Prolong Lifespan and Mitigate Amyloid-β Toxicity in C. elegans via Distinct Mechanisms

Improved Proteostasis in the Secretory Pathway Rescues Alzheimer’s Disease in the Mouse

Caenorhabditis Elegans As a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity.

A Deuterohemin Peptide Protects a Transgenic Caenorhabditis Elegans Model of Alzheimer’s Disease by Inhibiting Aβ1–42 Aggregation

Betaine reduces β-amyloid-induced paralysis through activation of cystathionine-β-synthase in an Alzheimer model of Caenorhabditis elegans

EXTENDING A HEALTHY LIFESPAN WITH 3-HYDROXYANTHRANILIC ACID

Treatment with 1, 10 Phenanthroline-5-Amine Reduced Amyloid Burden in a Mouse Model of Alzheimer's Disease

A New Target for the Treatment/Prevention of Cognitive Impairment in Schizophrenia, Dementia, and Aging

Cranberry Extract Standardized for Proanthocyanidins Alleviates Β-Amyloid Peptide Toxicity by Improving Proteostasis Through HSF-1 Incaenorhabditis Elegansmodel of Alzheimer’s Disease

Acetylcholineestarase-Inhibiting Alkaloids from Lycoris Radiata Delay Paralysis of Amyloid Beta-Expressing Transgenic C. Elegans Cl4176

Inhibiting Aβ Toxicity in Alzheimer's Disease by a Pyridine Amine Derivative.

Diterpenoid Caesalmin C Delays Aβ-Induced Paralysis Symptoms via the DAF-16 Pathway in Caenorhabditis elegans

A Novel Peroxidase Mimics And Ameliorates Alzheimer'S Disease-Related Pathology And Cognitive Decline In Mice